Follow The Filings

CGTX Cognition Therapeutics

Cognition Therapeutics earnings company data as of 7:50 PM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by CGTX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CGTX insider trades
  • $32K bought by 3 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. John Brendan Doyle CFO
    Buy
    $11K 10,000 shares at $1.13 +1.6% to stake
    Traded Apr 16 Filed Apr 20
    ↗
  2. Lisa Ricciardi CEO
    Buy
    $10K 9,175 shares at $1.10 +0.5% to stake
    Traded Apr 16 Filed Apr 20
    ↗
  3. Anthony Caggiano Chief Medical Officer
    Buy
    $11K 10,000 shares at $1.11 +1.2% to stake
    Traded Apr 16 Filed Apr 20
    ↗

Also filed in the last 12 months, not counted as buying or selling: 12 share withholdings for taxes and 11 stock grants.

SEC filings

Recent issuer filings from EDGAR, 21 shown.

Filed Form Detail Links
8-K 8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-K Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 1.01,1.02 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 1.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.